1	Head-to head comparison of anterior nares and nasopharyngeal swabs for SARS-CoV-2			
2	antigen detection in a community drive-through test centre in the UK			
3				
4	Rachel L Byrne ¹ , Ghaith Aljayyoussi ¹ , Konstantina Kontogianni ¹ , Karina Clerkin ¹ , Mathew			
5	McIntyre ¹ , Jahanara Wardale ¹ , Christopher T Williams ¹ , CONDOR steering group, Richard			
6	Body ² , Emily R Adams ^{1,3} , Margaretha de Vos ⁴ , Camille Escadafal ⁴ , Ana I Cubas Atienzar ¹ .			
7				
8	¹ Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK			
9	² Manchester University NHS Foundation Trust, UK			
10	³ Global Access Diagnostics, Bedfordshire, UK			
11	⁴ FIND, Geneva, Switzerland			
12				
13	* Corresponding author Ana I Cubas Atienzar <u>Ana.CubasAtienzar@lstmed.ac.uk</u>			
14				

- 15 Keywords: SARS-CoV-2, COVID-19, Nasal swabs, nasopharyngeal swabs, antigen detection,
- 16 RDT, LFA, head-to-head comparison.

17 Abstract:

Objective: To conduct a head-to-head diagnostic accuracy evaluation of professionally taken
 anterior nares (AN) and nasopharyngeal (NP) swabs for SARS-CoV-2 antigen detection using
 rapid diagnostic tests (Ag-RDT).

Methods: NP swabs for SARS-CoV-2 reverse transcription quantitative polymerase chain reaction (RT-qPCR) testing and paired AN and NP swabs for the antigen detection were collected from symptomatic participants enrolled at a community drive-through COVID-19 test centre in Liverpool. Two Ag-RDT brands were evaluated: Sure-Status (PMC, India) and Biocredit (RapiGEN, South Korea). The visual read out of the Ag-RDT test band was quantitative scored and the 50% and 95% limit of detection (LoD) of both Ag-RDT brands using AN and NP swabs was calculated using a probabilistic logistic regression model.

28 **Results:** A total of 604 participants were recruited of which 241 (40.3%) were SARS-CoV-2 29 positive by RT-qPCR. Sensitivity and specificity of AN swabs was equivalent to the obtained 30 with NP swabs: 83.2% (75.2-89.4%) and 98.8% (96.5-99.6%) utilising NP swabs and 84.0% 31 (76.2-90.1%) and 99.2% (97.0-99.8%) with AN swabs for Sure-Status and; 81.2% (73.1-87.7%) and 99.0% (94.7-86.5%) with NP swabs and 79.5% (71.3-86.3%) and 100% (96.5-32 33 100%) with AN swabs for Biocredit. The agreement of the AN and NP swabs was high for 34 both brands with an inter-rater relatability (κ) of 0.918 and 0.833 for Sure-Status and Biocredit, respectively. The overall 50% LoD and 95% LoD was $0.9-2.4 \times 10^4$ and $3.0-3.2 \times 10^8$ 35 RNA copies/mL for NP swabs and 0.3- 1.1×10^5 and 0.7-7.9 x 10^7 RNA copies/mL and for AN 36 37 swabs with no significant difference on LoD for any of the swabs types or test brands. 38 Quantitative read-out of test line intensity was more often higher when using NP swabs 39 with significantly higher scores for both Ag-RDT brands.

- 40 **Conclusions:** the diagnostic accuracy of the two SARS-CoV-2 Ag-RDTs brands evaluated in
- 41 this study was equivalent using AN swabs than NP swabs. However, test line intensity was
- 42 lower when using AN swabs which could influence negatively the interpretation of the Ag-
- 43 RDT results for lay users. Studies on Ag-RDT self-interpretation using AN and NP swabs are
- 44 needed to ensure accurate test use in the wider community.

45 Abstract word count: 345

46

47 Introduction

To meet the immense diagnostic demand of the COVID-19 pandemic, the development of rapid diagnostic tests for the detection of SARS-CoV-2 antigens (Ag-RDTs) became a priority [1]. Nasopharyngeal (NP) swabs are considered the standard of care for SARS-CoV-2 detection[2] and thus the majority of Ag-RDT kits are developed for NP swabs exclusively [1]. However, the use of anterior nasal (AN) swabs has been increasing as a less invasive alternative to promote access to testing in the community and facilitate mass testing programmes particularly in the UK [3].

55 For Ag-RDTs, studies on Ag-RDTs comparing sensitivity on AN swabs and NP swabs are very 56 limited, with only two reported studies performed on the same Ag-RDT brand, Standard-Q 57 (SD Biosensor, Inc., Korea), one study on professional taken swabs [6] and another in selftaken [7]. Sensitivity obtained with AN swabs was comparable (although 3% to 5% lower) 58 than with NP swabs sensitivity but neither of the swab types fulfilled WHO target product 59 60 profile (TPP) standards in any of the two studies [8]. AN swabs are considered accurate and clinically acceptable alternatives to NP swabs in outpatient settings for SARS-CoV-2 reverse 61 62 transcription polymerase chain reaction (RT-PCR) testing [4]. However, an in depth 63 metanalysis on SARS-CoV-2 RT-PCR testing found that anterior nares specimens were 12%-64 18% less sensitive than NP swabs [5].

The aim of this study was to perform a head-to-head evaluation on two World Health Organisation (WHO) approved or under assessment for Emergency Use listing (WHO-EUL) SARS-CoV-2 Ag-RDT brands marketed for AN and NP swabs: Sure-Status COVID-19 Antigen Card Test (Premier Medical Corporation, India) and Biocredit COVID-19 Antigen Test (RapiGEN, South Korea) respectively. This study is of particular interest in the UK as the use

of home Ag-RDTs on AN swabs has been integral to combatting the spread of COVID-19 during the pandemic [3], as on the 1st of April 2022 free national RT-PCR COVID-19 testing was suspended, with the purchase of Ag-RDTs using AN-swabs online or in pharmacies the only approach to access COVID-19 testing in a non-clinical setting.

74 Methods

75 Clinical evaluation

This was a prospective evaluation of consecutive participants enrolled at a community National Health Service (NHS) drive-through COVID-19 test centre located at the Liverpool John Lennon Airport. Two Ag-RDT brands were evaluated; Sure-Status COVID-19 Antigen Card Test (Premier Medical Corporation India) and Biocredit COVID-19 Antigen Test (RapiGEN, South Korea) referred as Sure-Status and Biocredit thereafter. The study progressed until at least 100 Ag-RDT positives using AN swabs in line with WHOs requirements for evaluation of alternative sample type [10].

All adults over the age of 18 who attended the drive-through test centre with symptoms of COVID-19 were asked to participate in the study. The symptoms included fever, cough, shortness of breath, tight chest, chest pain, runny nose, sore throat, anosmia, ageusia, headache, vomiting, abdominal pain, diarrhoea, confusion, rush, or tiredness. Participants were recruited under the Facilitating Accelerated COVID-19 Diagnostics (FALCON) study using verbal consent. Ethical approval was obtained from the National Research Ethics Service and the Health Research Authority (IRAS ID:28422, clinical trial ID: NCT04408170).

90 Swabs were collected following the same process with the NP swab collected first in one 91 nostril and placed in Universal Transport Media (UTM) (Copan Diagnostics Inc, Italy) for the

medRxiv preprint doi: https://doi.org/10.1101/2022.09.06.22279637; this version posted April 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

92 reference RT-qPCR test. This was followed by the collection of two swabs to evaluate the 93 Ag-RDTs, first an NP swab in the other nostril and finally a AN swab in both nostrils following 94 the manufacturer's instructions for use (IFU). Samples were given a unique identification 95 code and transported within cooler bags to the Liverpool School of Tropical Medicine 96 (LSTM) where samples were processed in category level 3 (CL3) containment laboratory 97 upon arrival.

Sure-Status and Biocredit Ag-RDTs were carried out following their instructions for use (IFU). The protocol for both Ag-RDT was the same when using AN and NP swabs. Results were read by two operators, blinded to one another and if a discrepant result occurred, a third operator acted as a tiebreaker. The visual read out of the Ag-RDT test band was scored on a quantitative scale from 1 (weak positive) - 10 (strong positive). Ag-RDT results were classified as invalid when the control line was absent.

104 RNA was extracted using the QIAamp[®] 96 Virus QIAcube[®] HT kit (Qiagen, Germany) on the 105 QIAcube[®] (Qiagen, Germany) and screened using TaqPath COVID-19 (ThermoFisher, UK) on 106 the QuantStudio 5[™] thermocycler (ThermoFisher, UK), an internal extraction control was 107 incorporated before the lysis stage, as recommended by the manufacturer. SARS-CoV-2 RT-108 qPCR result was considered (1) positive if any two of the three SARS-CoV-2 target genes (N 109 gene, ORF1ab and S gene) amplified with cycle threshold (Ct) \leq 40, (2) indeterminate if only one SARS-CoV-2 gene amplified and (3) negative if the internal extraction control amplified 110 111 and the SARS-CoV-2 target genes did not. Samples with invalid RT-qPCR results (no 112 amplification of the internal extraction control) were re-extracted and re-run once. Viral 113 loads in UTM swabs were measured with a ten-fold serial dilution standard curve of

quantified specific in vitro-transcribed RNA using five replicates for each standard curvepoint [11].

116 Statistical Analysis

117 Sensitivity, specificity, positive predicted value (PPV) and negative predictive values (NPV) 118 were calculated with 95% confidence intervals (CIs) by comparing the Ag-RDT results to the 119 RT-qPCR, as the reference standard. Sub-analyses of diagnostic performance were 120 performed by swab type (AN and NP), Ct-value ranges, onset of symptoms and vaccination 121 status using nonparametric statistics. The level of agreement between AN and NP swabs 122 was determined using Cohen's kappa (κ) [10]. The correlation between test line intensity 123 and viral loads were measured by Person correlation, coefficient (r_p) [12] and to further 124 analyse Ag-RDT sensitivities, we used logistic regression, with RNA copy numbers of the RT-125 gPCR NP swab and swab type (AN and NP) as independent variables and test outcomes as 126 the dependent variable, yielding detection probabilities for each viral load level. Statistical 127 analyses were performed using SPSS V.28.0, Epi Info V3.01 and R scripts. Statistical 128 significance was set at P < 0.05.

129 Results

130 Participant demographics

A total of 604 participants were recruited for this study, 372 recruited between August and October 2021 were enrolled for the Sure-Status Ag-RDT evaluation and 232 recruited between December 2021 and March 2022 were enrolled for the Biocredit Ag-RDT evaluation. Details of the demographics of the population of study are found in Table 1. Our study population had a mean age of 43 years (range 18-81, interquartile range [IQR] 33.0-

136	50.0), 348 (58%) were female and 566 were British (94%), with the remaining 36
137	participants being of other ethnic groups (n = 14), white background (n = 9), Asian (n = 8),
138	mix white and black backgrounds (n = 2) and Arab (n = 1). Three hundred and fourteen
139	participants of the 372 enrolled for the Sure-Status evaluation (84.4%) and 217 participants
140	of the 232 recruited for Biocredit (93.5%) received complete SARS-CoV-2 vaccination (2
141	doses). Additionally, 143 of the participants enrolled from December 2021 (61.6%) for the
142	Biocredit evaluation received a third dose as part of the UK booster roll out [13]. All
143	participants were symptomatic with a median onset of symptoms of 2 days (IQR 1-3). The
144	most common symptoms were cough (387, 64.3%), sore throat (232, 38.5%), headache
145	(203, 33.7%), fever (160, 26.6%), body aches (80, 13.3%) and runny nose (80, 13.3%) (Table
146	1).

Overall, 241 participants (40.3%, CI95% 36.3-44.4%) were SARS-CoV-2 positive by RT-qPCR,
6 had indeterminate RT-qPCR results and the remaining 355 were negative. Participants
with indeterminate RT-qPCR results were excluded from further analysis.

150 RT-qPCR positivity was significantly higher (p<0.05) among the participants enrolled for the 151 Biocredit evaluation cohort (53.7%, CI95% 47-60.4%) during December 2021 and March 152 2022 which coincided with the Omicron wave in the UK [14] than among the participants 153 enrolled between August and October 2021 (32.1%, CI95% 27.4-37.1%) when Delta was the 154 dominant SARS-CoV-2 variant.

155 Diagnostic evaluation

156 Sure Status

157 The overall sensitivity and specificity for the Sure-Status Ag-RDT compared to RT-qPCR was 83.2% (CI95% 75.2-89.4%) and 98.8% (CI95% 96.5-99.6%) utilising NP swabs and 84.0% 158 159 (CI95% 76.2-90.1%) and 99.2% (CI95% 97.0-99.8%) with AN swabs. For individuals with Cts < 160 25, the sensitivity was 91.8% (CI95% 84.5-96.4%) and 93.8% (CI95% 87.2-97.7%) for NP and 161 AN-swabs respectively. Seven Ag-RDTs gave invalid results, one NP swab (0.03%) sample and 162 six AN swab samples (1.6%). Participants with invalid Ag-RDTs results were excluded from 163 further analysis. Four SARS-CoV-2 positive cases were detected by NP only (3.4%) and six 164 cases were detected by AN only (5.0%) but this discrepancy on sensitivity between swab 165 types was not significant (P = 0.43). The percentage of agreement of NP and AN swab using 166 Sure-Status was 96.7% (95% CI 94.3-98.3%) and inter-rater reliability was almost perfect ($\kappa =$ 167 0.918). Inter-rater reliability was strong for both NP (κ = 0.871) and AN (κ = 0.852) swabs 168 when compared to RT-qPCR.

169 Biocredit

170 For the Biocredit Ag-RDT the sensitivity and specificity were 81.2% (CI95%73.1-87.7%) and 171 99.0% (Cl95%94.7-86.5%) with NP swabs and 79.5% (Cl95%71.3-86.3%) and 100% 172 (CI95%96.5-100%) with AN sampling compared to RT-qPCR. Sensitivity was 92.2% 173 (CI95%84.6-96.8%) and 95.5% (CI95%89.0-98.8%) using NP and AN swabs among 174 participants with Ct < 25. Ten SARS-CoV-2 positive cases were detected solely by NP (8.2%) and eight cases were detected only by AN (6.6%) but no significance on sensitivity was 175 176 observed between NP and AN swabs for this brand of Ag-RDTs either (P = 0.43). The 177 percentage of agreement of NP and AN swab for Biocredit was 91.6% (95% Cl 87.2-94.9%) 178 and inter-rater reliability was strong ($\kappa = 0.833$). Inter-rater reliability was moderate for both

179 NP ($\kappa = 0.790$) and AN ($\kappa = 0.782$) sampling compared to RT-qPCR. Diagnostic accuracy for 180 both Sure-Status and Biocredit is displayed in Table 2.

181 Head to head comparison of Sure Status and Biocredit

rWe report nosignificant difference in the diagnostic accuracy among participants with symptoms irrespective of days since onset, or vaccination status for all Ag-RDTs and swabbing combination (all *P* values > 0.05). Both Biocredit and Sure-Status Ag-RDTs using both swab types had better sensitivities on detecting SARS-CoV-2 antigens on individuals with Ct values < 25 than >30 (P = 0.029 in NP and P = 0.047 in AN for Sure-Status and P =0.018 and P = 0.001 for Biocredit).

188 The RNA copy numbers per mL (RNA copies/mL) of RT-PCR NP swabs was calculated and 189 statistically higher viral loads were obtained for the Sure-Status cohort than Biocredit (Fig 1) 190 measured by Kruskal–Wallis (P= 0.006). We determined the 50% and 95% limits of detection (LoD) for both Ag-RDT and swab types based on a logistic regression model (Fig 2). For Sure-191 Status, the RNA copies/mL for 50% LoD and 95% LoD were 2.4 \times 10⁴ and 3.16 \times 10⁸ for NP 192 193 specimen and 3.4 x 10^4 and 7.94 x 10^7 for AN swabs. For Biocredit, the RNA copies/mL for LoD50 and LoD95 were 9.12×10^3 and 3.02×10^8 for NP specimen and 1.12×10^5 and 6.76×10^8 194 10⁶ for AN swabs. Although the LoD95 was better for AN swabs for both Ag-RDT brands 195 196 (3.98 for Sure-Status and 44.67 for Biocredit), there was no statistical difference on LODs 197 neither by swab type and Ag-RDT brand (all P values > 0.05).

198 *Quantitative read-out analysis*

Quantitative read-out in paired positive AN and NP was more often higher for the NP (40
instances higher on NP and four higher on AN in Sure-Status; and 35 instances higher on NP

medRxiv preprint doi: https://doi.org/10.1101/2022.09.06.22279637; this version posted April 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

and 12 higher on AN in Biocredit) and gave significantly higher scores for both Ag-RDT, Sure-Status (P = 0.007) and Biocredit (P = 0.013) (Figure 1) measured by Kruskal–Wallis. Additionally, test lines scores were analysed by RNA copies/mL and these had a positive correlation. For Biocredit, strong correlation using AN swabs ($r_P = 0.727$) but moderate using NP swabs ($r_P = 0.591$). For Sure-Status, both swab types had a moderate correlation to viral loads (NP swab $r_P = 0.614$ and AN swab $r_P = 0.661$).

207 DISCUSSION

208 This is the first diagnostic clinical evaluation of Sure-Status Ag-RDT and results have shown a 209 satisfactory performance for both AN and NP swabs fulfilling the sensitivity (\geq 80%) and 210 specificity (\geq 97%) outlined in the target product profile (TPP) WHO standards [8]. For 211 Biocredit Ag-RDT, there are five studies to date that have evaluated the performance of NP 212 swabs reporting varied sensitivities from 52% to 85% [15]. In this study we report a higher 213 sensitivity (81.2% ,Cl95%73.1-87.7%) and specificity (99.0% ,Cl95%94.7-86.5%) of the 214 Biocredit Ag-RDT fulfilled the WHO standards using NP swab but underperformed in the 215 sensitivity (79.5%, Cl95% 71.3-86.3%) criteria when using AN.

216 Results presented here demonstrate that AN swabs are equivalent to NP swabs for SARS-217 CoV-2 Ag-RDT testing giving comparable sensitivities, 50% LoD and 95% LoD for both Ag-218 RDTs brands evaluated here. Our results supports previous findings where AN and NP swabs 219 were compared for the Ag-RDT Standard-Q (SD Biosensor, Inc., Korea) in Lesotho [6], but we 220 reported a higher sensitivity compared to the 67.3% and 70.2% for AN and NP swabs 221 previously described [6]. Studies on RT-qPCR have found lower sensitivity using AN swabs 222 compared to NP swabs consistently [5]. However, the difference in sensitivity was only significant for patients with viral loads $< 10^3$ copies/mL [16] and this threshold is not 223

relevant to Ag-RDTs of which the limit of detection ranges between 10⁴- 10⁸ RNA copies/mL
in swabs [11].

226 Quantitative assessment of the test line scores showed that test line intensity was 227 significantly higher on NP swabs than AN swabs. The line intensity is an important 228 component of home testing as studies have shown fainter lines are more difficult to 229 interpret for a lay person, likely due to lower signal intensity [17]. In an user experience 230 home based study, 77.1% of the cases that the participants interpreted wrongly as negative 231 being positive, were weak and moderate positives while only 22.9% were strong positives 232 [17]. The significantly lower intensity of the AN swab compared to NP swab is likely 233 attributed to the differences of SARS-CoV-2 viral loads in the respiratory tract. Studies have 234 found lower viral loads on AN swabs compared to NP swabs [16]. Statistical analysis 235 supported this hypothesis where a positive correlation between viral loads and Ag-RDT test 236 line scores was shown. Further implementation studies on Ag-RDT test results interpretation 237 by patients or within a home testing setting are urgently needed to drive self-testing to 238 scale.

This study has several strengths, the use of standardised sampling methods, independent blinded readers, robust statistical analysis, quantitative assessment of Ag-RDT test line results and the evaluation of one approved WHO-EUL Ag-RDT test brands (Sure-Status) and under review (Biocredit). Qualifying it to have high global public health relevance [18].

The main limitation of this study is that the AN swabs were always taken last. The order of sample collection could have negatively biased the results obtained for AN swabs caused by a possible sample depletion. However, in the two studies that compared Ag-RDT using AN swabs, the AN swab was collected first and our reported sensitivity and specificity for AN

medRxiv preprint doi: https://doi.org/10.1101/2022.09.06.22279637; this version posted April 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

swabs are greater than the previous studies [6,7]. Further, studies on RT-qPCR found lower sensitivity using AN swabs compared to NP swabs [5], even when AN swabs were collected first [15,18,19]. Thereby it is unlikely that the order of the swabs impacted sample availability for AN and NP sampling.

In conclusion, this study demonstrates the sensitivity of two SARS-CoV-2 Ag-RDTs using ANsampling are comparable to that of NP-sampling. AN-sampling can be performed with less training, reduces patient discomfort, and enables scaling up of antigen testing strategies. Test line intensity however is lower when using AN swabs which could influence negatively the interpretation of the Ag-RDT results. Additional studies on Ag-RDTs using AN swabs on self-interpretation by a lay person are needed and further education around how to interpret a positive Ag-RDT to the wider community.

258 Acknowledgements

Condor steering group: Dr A. Joy Allen, Dr Julian Braybrook, Professor Peter Buckle, Ms
Eloise Cook, Professor Paul Dark, Dr Kerrie Davis, Dr Gail Hayward, Professor Adam Gordon,
Ms Anna Halstead, Dr Charlotte Harden, Dr Colette Inkson, Ms Naoko Jones, Dr William
Jones, Professor Dan Lasserson, Dr Joseph Lee, Dr Clare Lendrem, Dr Andrew Lewington, Mx
Mary Logan, Dr Massimo Micocci, Dr Brian Nicholson, Professor Rafael Perera-Salazar, Mr
Graham Prestwich, Dr D. Ashley Price, Dr Charles Reynard, Dr Beverley Riley, Professor John
Simpson, Dr Valerie Tate, Dr Philip Turner, Professor Mark Wilcox, Dr Melody Zhifang.

We would like to acknowledge the participants for volunteering for this study and to the UK National Institute for Health Research Clinical Research Network and the COvid-19 National DiagnOstic Research & evaluation (CONDOR) programme. We also thank the CRN for their support during the study and Daisy Bengey, Rachel Watkins, and Lorna Finch for their help on sample collection and recruitment.

271 FUNDING

272 This work was funded as part of FIND's work as co-convener of the diagnostics pillar of the 273 Access to COVID-19 Tools (ACT) Accelerator, including support from Unitaid [grant number: 274 2019-32-FIND MDR], the governments of the Netherlands [grant number: MINBUZA-275 2020.961444] and from UK Department for International Development [grant number 300341-102]. The FALCON study was funded by the National Institute for Health Research, 276 277 Asthma UK and the British Lung Foundation.

278 REFERENCES

- 279 1 FIND. SARS-CoV-2 diagnostic pipeline. https://www.finddx.org/covid-19/pipeline/
- 280 2 Center of Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and
- 281 Testing Clinical Specimens for COVID-19. May 22. 2020.
- 282 3 GOV.UK. New campaign urges public to get tested twice a week. Published Online First:
- 283 2021.https://www.gov.uk/government/news/new-campaign-urges-public-to-get-tested-
- 284 twice-a-week
- 285 4 Péré H, Péré H, Péré H, et al. Nasal swab sampling for SARS-CoV-2: A convenient alternative 286 in times of nasopharyngeal swab shortage. J. Clin. Microbiol. 2020. doi:10.1128/JCM.00721-20
- 287
- 288 5 Zhou Y, OLeary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial 289 detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-Analysis. PLoS One.
- 290 2021. doi:10.1371/journal.pone.0254559
- 291 6 Labhardt, Niklaus D González Fernández L, Katende, Bulemba Muhairwe J, Bresser M, et al.
- 292 Head-to-head comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid

293 antigen testing in Lesotho. medRxiv Published Online First: 2022.

294 doi:10.1101/2021.12.29.21268505

295	7	Lindner AK, Nikolai O, Kausch F, <i>et al.</i> Head-to-head comparison of SARS-CoV-2 antigen-		
296		detecting rapid test with self-collected anterior nasal swab versus professional-collected		
297		nasopharyngeal swab. Eur Respir J		
298		2020; 57 :2003961.http://erj.ersjournals.com/lookup/doi/10.1183/13993003.03961-2020		
299	8	(WHO) WHO, R&D Blue Print WH (HQ). Target product profiles for priority diagnostics to		
300		support response to the COVID-19 pandemic v.1.0. Published Online First:		
301		2020.https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-		
302		priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1		
303	9	GOV.UK. People with a positive lateral flow test no longer required to take confirmatory PCR		
304		test. Published Online First: 2021.https://www.gov.uk/government/news/people-with-a-		
305		positive-lateral-flow-test-no-longer-required-to-take-confirmatory-pcr-test		
306	10	World Health Organization (WHO). Prequalification Teams D. Instructions and requirements		
307		for Emergency Use Listing (EUL) Submission: In vitro diagnostics detecting SARS-CoV-2 nucleic		
308		acid or antigen.		
309		https://extranet.who.int/pqweb/sites/default/files/documents/220317_PQDx_347_Version6		
310		_NAT-Ag.pdf		
311	11	Cubas-Atienzar, Ana I., Kontogianni K, Edwards T, et al. Limit of detection in different		
312		matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2. Sci		
313		<i>Rep</i> 2021; 11 :1–8. doi:https://doi.org/10.1038/s41598-021-97489-9		
314	12	Schober P, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. Anesth		
315		Analg Published Online First: 2018. doi:10.1213/ANE.000000000002864		
316	13	GOV.UK. Vaccinations in the UK. Coronavirus UK.		
317		2022.https://coronavirus.data.gov.uk/details/vaccinations		
318	14	Mahase E. Covid-19: Is the UK heading for another omicron wave? <i>BMJ</i> 2022; 376 .		

319		doi:https://doi.org/10.1136/bmj.o738
320	15	Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics
321		for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med. 2021.
322		doi:10.1371/journal.pmed.1003735
323	16	Callahan C, Lee R, Lee G, et al. Nasal-Swab Testing Misses Patients with Low SARS-CoV-2 Viral
324		Loads. <i>medRxiv</i> 2020.
325	17	Jing M, Bond R, Robertson LJ, et al. User experience of home-based AbC-19 SARS-CoV-2
326		antibody rapid lateral flow immunoassay test. <i>Sci Rep</i> 2022; 12 :1173. doi:10.1038/s41598-
327		022-05097-у
328	18	World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic — Emergency
329		Use Listing Procedure (EUL) open for IVDs. Prequalification Med. Prod. (IVDs, Med. Vaccines
330		Immun. Devices, Vector Control. https://extranet.who.int/pqweb/vitro-
331		diagnostics/coronavirus-disease-covid-19-pandemic-—-emergency-use-listing-procedure-eul-
332		open
333	19	Hanson KE, Barker AP, Hillyard DR, et al. Self-collected anterior nasal and saliva specimens
334		versus health care worker-collected nasopharyngeal swabs for the molecular detection of
335		SARS-CoV-2. J Clin Microbiol Published Online First: 2020. doi:10.1128/JCM.01824-20
336	20	Tu Y-P, Jennings R, Hart B, et al. Swabs Collected by Patients or Health Care Workers for
337		SARS-CoV-2 Testing. <i>N Engl J Med</i> Published Online First: 2020. doi:10.1056/nejmc2016321
338		
339		
340		
341		



343



344



reference standard for the participants enrolled for Sure-Status and Biocredit Ag-RDT evaluation.

347 The whiskers show the maximum and minimum values and the vertical line the median. Asterisks

- 348 indicate statistical significance between AN and NP swab types.
- 349
- 350

351



Figure 2. Limit of detection analyses of upper-respiratory samples positive by RT-qPCR for Sure-Status and Biocredit using AN and NP swabs. The log10 RNA copies on the x axis were plotted against a positive (1.0) or negative (0.0) Ag-RDT result on the y axis. Green (Sure-Status) and purple (Biocredit) curves show logistic regressions of the viral load on the Ag-RDT result; vertical dashed lines indicate log10 RNA copies subjected to the test at which 50% and 95% LoD of the samples are expected positive based on the regression results. No significant differences were observed.

359

360





375 **Table 1.** Demographics of the population of study for Sure-Status and Biocredit cohorts

	Sure-Status	Biocredit	All
Total	372	232	604
Age [mean (min-max), IQR]	43 (18-81), 33-53	43 (18-78), 33-51	43 (18-81), 33-52
Gender [%F, (n/N)] IQR]	57%, (211/372)	59%, (137/232)	58%, (348/602)
Triple vaccinated (n, %)	NA*	143 (61.6%)	143 (23.8%)
Double vaccinated (n, %)	314 (84.4%)	74 (40%)	388 (64.4%)
Partially vaccinated (n, %)	29 (7.8%)	4 (1.7%)	33 (5.5%)
Not vaccinated (n, %)	27 (7.3%)	10 (4.3%)	37 (6.2%)
Vaccination not disclosed (n, %)	2 (0.5)	1 (0.3%)	3 (0.5%)
Days symptoms onset [median (IQR); N]	2 (1-3), 371	2 (1-3), 232	2 (1-3), 601
Days 0-3 (n, %)	304, 81.7%	186, 80.2%	490, 81.1%
Days 4-7 (n, %)	56, 15.1%	41, 17.7%	97, 16.1%
Days 8+ (n, %)	10, 2.7%	5, 2.2%	15, 2.5%
RT-qPCR SARS-CoV-2 Positivity [%, (n/N)]	32.1%, (119/371)	53.7%, (122/227)	40.3% (241/598)
Symptom [total n (%), in RT-qPCR positive n			
(%)]			
Cough	248 (66.7%), 73 (61.3%)	139 (60.0%), 71 (58.2%)	387 (64.3%), 144 (60.0%)
Sore throat	129 (34.7%), 34 (28.6%)	103 (44.4%), 56 (45.9%)	232 (38.5%), 90 (37.4%)
Headache	123 (33.1%), 57 (47.9%)	80 (34.5%), 45 (36.9%)	203 (33.7%), 102 (42.3%)
Fever	106 (28.5%), 30 (25.2%)	54 (23.3%), 28 (22.9%)	160 (26.6%), 58 (24.1%)
Body aches	41 (11.0%), 21 (17.7%)	39 (16.8%), 29 (23.8%)	80 (13.3%), 51 (21.2%)
Runny nose	39 (13.2%), 20 (16.8%)	41 (17.7%), 31 (25.4%)	80 (13.3%), 51 (21.2%)
Loss taste	48 (12.9%), 19 (16.0%)	19 (8.2%), 10 (8.2%)	67 (11.1%), 29 (12.0%)
Loss smell	29 (7.8%), 9 (7.6%)	14 (6.0%), 7 (5.7%)	43 (7.1%), 16 (6.6%)
Chest pain	18 (4.8%),7 (5.9%)	12 (5.2%), 8 (6.6%)	30 (5.0%), 15 (6.2%)
Fatigue	13 (3.5%), 4 (3.4)	17 (7.3%), 10 (8.2%)	30, (5.0%), 14 (5.8%)
Shortness of breath/tight chest	13 (3.5%), 3 (2.5%)	9 (3.9%), 5 (4.1%)	22 (3.6%), 15 (6.2%)
Vomiting	11 (3%), 5 (4.2%)	2 (8.6%), 2 (1.6%)	13 (2.2%), 7 (2.9%)
Diarrhoea	9 (2.4%), 3 (2.5%)	3 (13%), 3 (2.5%)	12 (2.0%), 6 (2.5%)
Abdominal pain	6 (1.6%), 3 (2.5%)	1 (0.4%), 1 (0.8%)	7 (1.2%), 4 (1.7%)
Rash	3 (0.8%), 0 (0.0%)	1 (0.4%), 1 (0.8%)	4 (0.6%), 1 (0.4%)
Confusion	1 (0.3%), 0 (0.0%)	0 (0%)	1 (0.2%), 0 (0%)
	159 (42.7%), 68 (57.4%)	134 (57.8%), 85 (69.7%)	293 (48.7%), 153
Other			(63.5%)

376 *Participants were enrolled before booster rolled out in the UK

377

378

³⁷⁴

380

All Ct values TP FP TΝ FN Sensitivity Specificity NPV **PPV** Sure-Status 200 5 494 38 83.9 (78.3-88.1) 99.0 (97.7-99.7) 92.7(90.5-94.4) 97.6 (94.3-98.9) 83.2 (75.2-89.4) NP swab 99 2 249 20 98.8 (96.5-99.6) 91.7 (88.4-94.2) 97.1 (91.44-99.03) AN swab 101 2 245 18 84.0 (76.2-90.1) 99.2 (97.0-99.8) 92.8 (89.5-95.1) 98.0 (92.62-99.5) Biocredit 196 1 209 48 80.3 (74.8-85.1) 99.1 (95.0-99.9) 81.3(77.2-84.9) 99.5 (96.5-100) NP swab 99 1 104 23 81.2 (73.1-87.7) 99.0 (94.7-86.5) 81.9 (73.99-85.2) 99.0 (93.4-99.9) AN swab 97 0 105 25 79.5 (71.3-86.3) 100 (96.5-100) 80.8 (74.8-85.6) 100 (100-100) All NP 198 4 353 43 82.2 (76.7-86.8) 98.9 (97.2-99.7) 89.1 (86.2-91.5) 98.0 (94.9-99.2) 198 2 All AN 350 43 82.2 (76.7-86.8) 99.4 (97.9-99.9) 89.1 (86.2-91.5) 99.0 (96.1-99.8)

381 Table 2. Clinical sensitivity and specificity of Sure-Status and Biocredit using NP and Nasal Swab